Citius Pharmaceuticals Files 8-K
Ticker: CTXR · Form: 8-K · Filed: May 21, 2024 · CIK: 1506251
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Update
TL;DR
Citius Pharma filed an 8-K, standard update.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on May 21, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a notification of these items.
Why It Matters
This filing indicates that Citius Pharmaceuticals is providing updates on its corporate activities and financial status to the SEC, which is standard procedure for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- 001-38174 (identifier) — Commission File Number
- 27-3425913 (identifier) — IRS Employer Identification No.
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
- May 21, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing for Citius Pharmaceuticals, Inc.?
The 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on May 21, 2024.
What is Citius Pharmaceuticals, Inc.'s state of incorporation?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the address of Citius Pharmaceuticals, Inc.'s principal executive offices?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Does this filing provide specific financial details or event descriptions?
The provided text of the 8-K filing indicates the categories of information being reported (Other Events, Financial Statements and Exhibits) but does not include the specific details or figures within those categories.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-05-21 16:05:34
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0206620-8k_citius.htm (8-K) — 28KB
- ea020662001ex99-1_citius.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-24-045573.txt ( ) — 244KB
- ctxr-20240521.xsd (EX-101.SCH) — 3KB
- ctxr-20240521_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240521_pre.xml (EX-101.PRE) — 22KB
- ea0206620-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 21, 2024, we issued a press release announcing positive topline results of our pivotal Phase 3 clinical trial of Mino-Lok in patients with central line-associated infections or catheter-related bloodstream infections. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated May 21, 2024. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: May 21, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2